Cargando…
Buprenorphine Dispensing in Pennsylvania During the COVID-19 Pandemic, January to October 2020
Autores principales: | Chalasani, Rohan, Shinabery, Jared M., Goetz, Carrie Thomas, Chang, Chung-Chou H., Yang, Qingnan, Suda, Katie J., Gellad, Walid F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354093/ https://www.ncbi.nlm.nih.gov/pubmed/34378112 http://dx.doi.org/10.1007/s11606-021-07083-y |
Ejemplares similares
-
Characteristics of Hydroxychloroquine Dispensing in the United States, January to May 2020
por: Levin, Zachary, et al.
Publicado: (2021) -
Estimated Cases Averted by COVID-19 Digital Exposure Notification, Pennsylvania, USA, November 8, 2020–January 2, 2021
por: Jeon, Seonghye, et al.
Publicado: (2023) -
Marked Increase in Sales of Erectile Dysfunction Medication During COVID-19
por: Hernandez, Inmaculada, et al.
Publicado: (2021) -
A nationwide survey of antimicrobial dispensation practices in pharmacies and bodegas in the Dominican Republic
por: Mena Lora, Alfredo J., et al.
Publicado: (2022) -
Buprenorphine Telehealth Treatment Initiation and Follow-Up During COVID-19
por: Samuels, Elizabeth A., et al.
Publicado: (2022)